1-9 of 9
Michael Emig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz
Journal: Blood
Blood (2024) 144 (Supplement 1): 3052.
https://doi.org/10.1182/blood-2024-193896
Published: 2024
Journal Articles

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur, Lori Griffin, Melissa Barnett, Christina Ganesh, Zephanie Borneo, Roland L. Bassett, Lucila Nassif Kerbauy, Rafet Basar, Mecit Kaplan, Daniel Esqueda, Jeremy Ramdial, Sairah Ahmed, Chitra Hosing, Samer A. Srour, Amin Alousi, Muzaffar H. Qazilbash, Raphael Eric Steiner, Karenza Alexis, Michael Emig, Andreas Harstrick, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood
Blood (2023) 142 (Supplement 1): 774.
https://doi.org/10.1182/blood-2023-172980
Published: 2023
Journal Articles

AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)

Alison Moskowitz, Andreas Harstrick, Michael Emig, Andre Overesch, Sheena Pinto, Paulien Ravenstijn, Thomas Schlüter, Jennifer Rubel, Hans Rebscher, Thorsten Graefe, John Lim, Heather Raymon, Karenza Alexis
Journal: Blood
Blood (2023) 142 (Supplement 1): 4855.
https://doi.org/10.1182/blood-2023-174250
Published: 2023
Journal Articles

Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Yago Nieto, Pinaki P Banerjee, Indreshpal Kaur, Lori Griffin, Christina Ganesh, Lucila Kerbauy, Rafet Basar, Mecit Kaplan, Sanjida Islam, Daniel Esqueda, Roland Bassett, Melissa Timmons, Jeremy L. Ramdial, Samer A Srour, Neeraj Saini, Chitra Hosing, Sairah Ahmed, Swaminathan Padmanabhan Iyer, Karenza Alexis, Michael Emig, Andreas Harstrick, Elizabeth J Shpall, Katy Rezvani
Journal: Blood
Blood (2022) 140 (Supplement 1): 415–416.
https://doi.org/10.1182/blood-2022-156125
Published: 2022
Journal Articles

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Martin C. Mueller, MD, Philipp Erben, MD, Giuseppe Saglio, MD, Enrico Gottardi, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Stephanie Lauber, MD, Michael Emig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 1991.
https://doi.org/10.1182/blood.V106.11.1991.1991
Published: 2005
Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 497.
https://doi.org/10.1182/blood.V106.11.497.497
Published: 2005
Journal Articles

Early Detection of Imminent Hematologic Relapse Due to BCR-ABL Kinase Domain Mutations in CML Patients on Imatinib Therapy by D-HPLC.

Thomas Ernst, MD, Philipp Erben, MD, Thomas Schenk, MD, Martin C. Mueller, MD, Michael Emig, MD, Sebastian Kreil, MD, Paul La Rosée, MD, Ute Berger, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 1088.
https://doi.org/10.1182/blood.V106.11.1088.1088
Published: 2005
Journal Articles

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Clinical Trials & Observations
Amy V. Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Lingyan Zhang, Joannah Score, Rachel Seear, Andrew J. Chase, Francis H. Grand, Helen White, Christine Zoi, Dimitris Loukopoulos, Evangelos Terpos, Elisavet-Christine Vervessou, Beate Schultheis, Michael Emig, Thomas Ernst, Eva Lengfelder, Rüdiger Hehlmann, Andreas Hochhaus, David Oscier, Richard T. Silver, Andreas Reiter, Nicholas C. P. Cross
Journal: Blood
Blood (2005) 106 (6): 2162–2168.
https://doi.org/10.1182/blood-2005-03-1320
Published: 2005
Journal Articles

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Andreas Hochhaus, Andreas Reiter, Susanne Saußele, Anja Reichert, Michael Emig, Jaspal Kaeda, Beate Schultheis, Ute Berger, Patricia C. A. Shepherd, Norman C. Allan, Rüdiger Hehlmann, John M. Goldman, Nicholas C. P. Cross
Journal: Blood
Blood (2000) 95 (1): 62–66.
https://doi.org/10.1182/blood.V95.1.62
Published: 2000